#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Osteoporosis in men


Authors: Jan Štěpán
Authors place of work: Revmatologický ústav, Praha
Published in the journal: Čas. Lék. čes. 2016; 155: 340-348
Category: Review Articles

Summary

The health burden of osteoporosis in men is expected to increase with an aging population and increasing life expectancy. Both hip and vertebral fractures are associated with increased morbidity and mortality in men. The clinical evaluation, measurement of bone mineral density using dual-energy X-ray absorptiometry, laboratory tests and fracture risk assessment is now recognized as the standard for diagnosis of osteoporosis in males, and a preferred approach to guide treatment decisions. Clinical trials have demonstrated efficacy of several treatment options available for men with osteoporosis. Moreover, clinical interventions to improve physical performance could also reduce the risk of future fractures.

Keywords:
epidemiology, bone densitometry, osteoporosis, prevention, risk of fracture, therapy


Zdroje

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285(6): 785–795.

2. Melton LJ 3rd. Epidemiology of fractures. In: Riggs BL, Melton LJ 3rd (eds.): Osteoporosis: etiology, diagnosis and management. Raven Press, New York, 1995: 133–154.

3. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005; 16 Suppl. 2: S3–S7.

4. Svedbom A, Hernlund E, Ivergård M et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8(137): 35–42.

5. Štěpán JJ, Vaculík J, Pavelka K et al. Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model. Calcif Tissue Int 2012; 90(5): 365–372.

6. von Friesendorff M, McGuigan FE, Besjakov J, Akesson K. Hip fracture in men-survival and subsequent fractures: a cohort study with 22-year follow-up. J Am Geriatr Soc 2011; 59(5): 806–813.

7. Bliuc D, Nguyen ND, Milch VE et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301(5): 513–521.

8. Poor G, Atkinson EJ, Lewallen DG et al. Age-related hip fractures in men: clinical spectrum and short-term outcomes. Osteoporos Int 1995; 5(6): 419–426.

9. Magaziner J, Simonsick EM, Kashner TM et al. Survival experience of aged hip fracture patients. Am J Public Health 1989; 79(3): 274–278.

10. Seeman E. Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab 2001; 86(10): 4576–4584.

11. Kirmani S, Christen D, van Lenthe GH et al. Bone structure at the distal radius during adolescent growth. J Bone Miner Res 2009; 24(6): 1033–1042.

12. Riggs BL, Melton LJ 3rd, Robb RA et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 2004; 19(12): 1945–1954.

13. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab 2010; 95(1): 3–10.

14. Cohen-Solal ME, Baudoin C, Omouri M et al. Bone mass in middle-aged osteoporotic men and their relatives: familial effect. J Bone Miner Res 1998; 13(12): 1909–1914.

15. Van Pottelbergh I, Goemaere S, Zmierczak H et al. Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men: evidence from a three-generation family study. J Bone Miner Res 2003; 18(2): 303–311.

16. Ferrari SL, Deutsch S, Baudoin C et al. LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone 2005; 37(6): 770–775.

17. Pernow Y, Hauge EM, Linder K et al. Bone histomorphometry in male idiopathic osteoporosis. Calcif Tissue Int 2009; 84(6): 430–438.

18. Ostertag A, Collet C, Chappard C et al. A case-control study of fractures in men with idiopathic osteoporosis: Fractures are associated with older age and low cortical bone density. Bone 2013; 52(1): 48–55.

19. Seeman E. Pathogenesis of osteoporosis. J Appl Physiol 2003; 95(5): 2142–2151.

20. Aaron JE, Makins NB, Sagreiya K. The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop 1987; 215: 260–271.

21. Riggs BL, Melton LJ, Robb RA et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 2008; 23(2): 205–214.

22. Kelepouris N, Harper KD, Gannon F et al. Severe osteoporosis in men. Ann Intern Med 1995; 123(6): 452–460.

23. Schaffler MB, Choi K, Milgrom C. Aging and matrix microdamage accumulation in human compact bone. Bone 1995; 17(6): 521–525.

24. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002; 359(9320): 1841–1850.

25. Kanis JA, Bianchi G, Bilezikian JP et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int 2011; 22(11): 2789–2798.

26. Watts NB, Adler RA, Bilezikian JP et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97(6): 1802–1822.

27. Ferrini RL, Barrett Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 1998; 147(8): 750–754.

28. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86(8): 3555–3561.

29. Mellstrom D, Vandenput L, Mallmin H et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008; 23(10): 1552–1560.

30. Frost M, Nielsen TL, Brixen K, Andersen M. Peak muscle mass in young men and sarcopenia in the ageing male. Osteoporos Int 2015; 26(2): 749–756.

31. Rezaei A, Dragomir-Daescu D. Femoral strength changes faster with age than BMD in both women and Men: A biomechanical study. J Bone Miner Res 2015; 30(12): 2200–2206.

32. Ferretti JL, Capozza RF, Cointry GR et al. Gender-related differences in the relationship between densitometric values of whole-body bone mineral content and lean body mass in humans between 2 and 87 years of age. Bone 1998; 22(6): 683–690.

33. Edwards MH, Dennison EM, Aihie Sayer A et al. Osteoporosis and sarcopenia in older age. Bone 2015; 80: 126–130.

34. Madeira E, Mafort TT, Madeira M et al. Lean mass as a predictor of bone density and microarchitecture in adult obese individuals with metabolic syndrome. Bone 2013; 59C: 89–92.

35. Pham HM, Nguyen ND, Center JR et al. Contribution of quadriceps weakness to fragility fracture: A prospective study. J Bone Miner Res 2016; 31(1): 208–214.

36. Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab Clin North Am 2007; 36(2): 399–419.

37. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organisation; Geneva, 1994.

38. Rosa J, Šenk F, Palička V. Diagnostika a léčba postmenopauzální osteoporózy. Stanovisko Společnosti pro metabolická onemocnění skeletu ČLS JEP 2015. Osteologický bulletin 2016; 20(4): 150–168.

39. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 2000; 11(3): 192–202.

40. Kanis JA, McCloskey EV, Johansson H et al. A reference standard for the description of osteoporosis. Bone 2008; 42(3): 467–475.

41. Looker AC, Wahner HW, Dunn WL et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998; 8(5): 468–489.

42. Official Positions of the International Society for Clinical Densitometry. Dostupné na: https: //iscd.app.box.com/v/op-iscd-2015-adult

43. Looker AC, Orwoll ES, Johnston CC jr. et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997; 12(11): 1761–1768.

44. Schuit SC, van der Klift M, Weel AE et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34(1): 195–202.

45. Pasco JA, Lane SE, Brennan SL et al. Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data. Osteoporos Int 2014; 25(3): 857–862.

46. Bliuc D, Alarkawi D, Nguyen TV et al. Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2015; 30(4): 637–646.

47. Nguyen TV, Center JR, Eisman JA. Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res 2005; 20(7): 1195–1201.

48. Leslie WD, Majumdar SR, Morin SN, Lix LM. Why does rate of bone density loss not predict fracture risk? J Clin Endocrinol Metab 2015; 100(2): 679–683.

49. Hui SL, Slemenda CW, Johnston CC jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81(6): 1804–1809.

50. Kanis JA, Borgstrom F, De Laet C et al. Assessment of fracture risk. Osteoporos Int 2005; 16(6): 581–589.

51. Kanis JA, McCloskey EV, Johansson H et al. Development and use of FRAX in osteoporosis. Osteoporos Int 2010; 21 Suppl. 2: S407–S413.

52. Assessment of osteoporosis at the primary health care level. Report of a WHO Study Group. Kanis JA (ed). University of Sheffield Medical School, Sheffield, UK, 2007.

53. Leslie WD, Lix LM. Comparison between various fracture risk assessment tools. Osteoporos Int 2014; 25(1): 1–21.

54. Fraser LA, Langsetmo L, Berger C et al. Fracture prediction and calibration of a Canadian FRAX(R) tool: a population-based report from CaMos. Osteoporos Int 2011; 22(3): 829–37.

55. Ettinger B, Ensrud KE, Blackwell T et al. Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 2013; 24(4): 1185–1193.

56. Ho-Pham LT, Nguyen UD, Nguyen TV. Association between lean mass, fat mass, and bone mineral density: a meta-analysis. J Clin Endocrinol Metab 2014; 99(1): 30–38.

57. Forsen L, Bjorndal A, Bjartveit K et al. Interaction between current smoking, leanness, and physical inactivity in the prediction of hip fracture. J Bone Miner Res 1994; 9(11): 1671–1678.

58. Duckham RL, Masud T, Taylor R et al. Randomised controlled trial of the effectiveness of community group and home-based falls prevention exercise programmes on bone health in older people: the ProAct65+ bone study. Age Ageing 2015; 44(4): 573–579.

59. Bello M, Sousa MC, Neto G et al. The effect of a long-term, community-based exercise program on bone mineral density in postmenopausal women with pre-diabetes and type 2 diabetes. J Hum Kinet 2014; 43: 43–48.

60. McNamara A, Gunter K. The influence of participation in Better Bones and Balance on skeletal health: evaluation of a community-based exercise program to reduce fall and fracture risk. Osteoporos Int 2012; 23(6): 1813–1822.

61. Gianoudis J, Bailey CA, Ebeling PR et al. Effects of a targeted multimodal exercise program incorporating high-speed power training on falls and fracture risk factors in older adults: a community-based randomized controlled trial. J Bone Miner Res 2014; 29(1): 182–191.

62. Watson SL, Weeks BK, Weis LJ et al. Heavy resistance training is safe and improves bone, function, and stature in postmenopausal women with low to very low bone mass: novel early findings from the LIFTMOR trial. Osteoporos Int 2015; 26(12): 2889–2894.

63. Colaianni G, Cuscito C, Mongelli T et al. The myokine Irisin increases cortical bone mass. PNAS 2015; 112: 12157–12162.

64. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag 2008; 4(1): 269–286.

65. Mikyas Y, Agodoa I, Yurgin N. A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men. Appl Health Econ Health Policy 2014; 12(3): 267–277.

66. Greenspan SL, Perera S, Ferchak MA et al. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med 2015; 175(6): 913–921.

67. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343(9): 604–610.

68. Boonen S, Orwoll ES, Wenderoth D et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009; 24(4): 719–725.

69. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int 2009; 29(3): 311–315.

70. Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005; 64(5): 811–816.

71. Sato Y, Kanoko T, Satoh K, Iwamoto J. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med 2005; 165(15): 1737–1742.

72. Orwoll ES, Binkley NC, Lewiecki EM et al. Efficacy and safety of monthly ibandronate in men with low bone density. Bone 2010; 46(4): 970–976.

73. Orwoll ES, Miller PD, Adachi JD et al. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010; 25(10): 2239–2250.

74. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357(18): 1799–1809.

75. Boonen S, Orwoll E, Magaziner J et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 2011; 59(11): 2084–90.

76. Boonen S, Reginster JY, Kaufman JM et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367: 1714–1723.

77. Sambrook PN, Roux C, Devogelaer JP et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 2012; 50(1): 289–295.

78. Langdahl BL, Teglbjaerg CS, Ho PR et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 2015; 100(4): 1335–1342.

79. Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361(8): 745–755.

80. Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361(8): 756–765.

81. Ringe JD, Dorst A, Farahmand P. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung 2010; 60(5): 267–272.

82. Kaufman JM, Audran M, Bianchi G et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 2013; 98(2): 592–601.

83. Jonville-Bera AP, Autret-Leca E. Adverse drug reactions of strontium ranelate (Protelos) in France. Presse Med 2011; 40(10): e453–e462.

84. Khan AA, Morrison A, Hanley DA et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30(1): 3–23.

85. Suri S, Monkkonen J, Taskinen M et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 2001; 29(4): 336–343.

86. Iwata K, Li J, Follet H, Phipps RJ, Burr DB. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 2006; 39(5): 1053–1058.

87. Ma YL, Zeng QQ, Chiang AY et al. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone 2014; 59: 139–147.

88. Idris AI, Rojas J, Greig IR et al. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008; 82(3): 191–201.

89. Adler RA, El-Hajj Fuleihan G, Bauer DC et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016; 31(1): 16–35.

90. Lindsay R, Krege JH, Marin F, Jin L, Štěpán JJ. Teriparatide for osteoporosis: importance of the full course. Osteoporos Int 2016; 27(8): 2395–2410.

91. Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18(1): 9–17.

92. Kaufman JM, Orwoll E, Goemaere S et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005; 16(5): 510–516.

93. Gluer CC, Marin F, Ringe JD et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 2013; 28(6): 1355–1368.

94. Walker MD, Cusano NE, Sliney J et al. Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 2013; 44: 237–246.

95. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev 2008; 29(4): 441–464.

96. Gielen E, Vanderschueren D, Callewaert F, Boonen S. Osteoporosis in men. Best Pract Res Clin Endocrinol Metab 2011; 25(2): 321–335.

97. Ebeling PR. Osteoporosis in men. N Engl J Med 2008; 358(14): 1474–1482.

98. Chen LX, Zhou ZR, Li YL et al. Comparison of bone mineral density in lumbar spine and fracture rate among eight drugs in treatments of osteoporosis in men: a network meta-analysis. PLoS One 2015; 10(5): e0128032.

Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#